Bioretec (FRA:0TN) Total Receivables: €1.20 Mil (As of Dec. 2025)


What is Bioretec Total Receivables?

Bioretec FRA:0TN Total Receivables is €1.20 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Bioretec's Total Receivables for the quarter that ended in Dec. 2025 was €1.20 Mil.

Bioretec Total Receivables Historical Data

* Premium members only.

The historical data trend for Bioretec's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioretec Total Receivables Chart

Bioretec Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial 0.46 0.56 1.63 1.96 1.20

Bioretec Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.63 1.56 1.96 2.44 1.20

Bioretec Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €1.20 Mil mean?
Bioretec (FRA:0TN) has a Total Receivables of €1.20 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Bioretec and its competitors.
Is Bioretec's Total Receivables too high?
Bioretec's current Total Receivables is €1.20 Mil.
How does Bioretec's Total Receivables compare to ABT and SYK?
Bioretec's Total Receivables of €1.20 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Devices & Instruments company?
A good Total Receivables depends on the Medical Devices & Instruments industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Bioretec and its competitors. Bioretec's current Total Receivables is €1.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioretec stock overvalued right now?
Based on GuruFocus' analysis, Bioretec (FRA:0TN) is currently considered Possible Value Trap. The stock's GF Value™ is €0.18, compared to a current price of €0.02 — trading 88.9% below its estimated fair value. The current Total Receivables is €1.20 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Bioretec (FRA:0TN), the current Total Receivables is €1.20 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioretec Business Description

Other Exchanges BRETEC:Finland
Address Yrittajankulma 5, Tampere, FIN, 33710
Bioretec Ltd is a medical device company focusing on the development of bioabsorbable and bioresorbable implants for pediatric and adult orthopedics. It has developed the following product lines: RemeOs and Activa. RemeOs is based on a high-performance magnesium alloy and hybrid composite, introducing absorbable materials for enhanced surgical outcomes. The RemeOs implants (RemeOs Screw Lag, RemeOs Screw Lag Solid, RemeOs Screw FT, etc.) are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The Activa implants (ActivaPin, ActivaNail, ActivaScrew, etc.) are based on fully absorbable biopolymer products that facilitate natural bone healing without requiring removal surgery.